StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories established Pharmaceutical Products Segment Total — Reported Sales Growth (%) (%)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

Latest, Q3 2026
6.8%
Period ended Sep 30, 2026
Change on a year earlier
-0.7 pts
7.5% in Q3 2025
History
44 quarters
Since Q4 2015
Sources
44
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEstablished Pharmaceutical Products Segment Total — Reported Sales Growth (%) (%)Year on yearSource
Q3 2026Sep 30, 20266.8%-0.7 ptsSEC Filing (0001628280-26-066601) ↗
Q2 2026Jun 30, 20268.4%+1.5 ptsSEC Filing (0001628280-26-048377) ↗
Q1 2026Mar 31, 202613.2%+10.5 ptsSEC Filing (0001628280-26-025365) ↗
Q4 2025Dec 31, 20259.0%+5.2 ptsSEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 20257.5%+4.8 ptsSEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 20256.9%+6.3 ptsSEC Filing (0001628280-25-035135) ↗
Q1 2025Mar 31, 20252.7%-0.4 ptsSEC Filing (0001628280-25-017924) ↗
Q4 2024Dec 31, 20243.8%+3.3 ptsSEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 20242.7%-0.5 ptsSEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 20240.6%-4.6 ptsSEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 20243.1%-0.6 ptsSEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 20230.5%-0.5 ptsSEC Filing (0001628280-24-002009) ↗
Q3 2023Sep 30, 20233.2%-1.7 ptsSEC Filing (0001628280-23-034544) ↗
Q2 2023Jun 30, 20235.2%+1.5 ptsSEC Filing (0001628280-23-025156) ↗
Q1 2023Mar 31, 20233.7%-3.4 ptsSEC Filing (0001628280-23-012020) ↗
Q4 2022Dec 31, 20221.0%-3.9 ptsSEC Filing (0001628280-23-001516) ↗

Cite this data

StockData. (2026). Abbott Laboratories Established Pharmaceutical Products Segment Total — Reported Sales Growth (%) (%), quarterly Q4 2015–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/epd-tot-yoy-rep

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.